Ex Vivo Drug Response Evaluation for Next Generation Care of Brain Metastases

Inclusion Criteria

• •Patients must be 18 years or older on the day of signing the informed consent, female or male.
• •Patients must have a Karnofsky performance status of 60 or more
• •Patients must have limited systemic therapeutic options as per treating physician judgement. The number of previous lines of therapies is not limited.
• •Patients with a tumor with a targetable oncogenic driver mutation should have already been treated with a targeted agent and options must have been exhausted.
• •Patients must have a clinical indication for surgery for probable brain metastasis
• •Patients will be considered eligible for the study only if the diagnosis of brain metastasis has been histologically confirmed on the sample obtained during the surgery performed after signing the informed consent form for the trial.
• •Any type of primary cancer is allowed: breast cancer, lung cancer, melanoma, other cancers. Patients may have several primary cancers.
• •Patients must have adequate bone marrow, renal and hepatic function documented at screening before surgery
• •Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test
• •Patients must have the ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and return for the required assessments.
• •Written informed consent for study participation must be signed and dated by the patient and the investigator prior to any study-related intervention.